ライフサイエンスコーパス: percutaneous coronary revascularization

1 stenting has emerged as the dominant form of percutaneous coronary revascularization.

2 icantly reduces the risk of restenosis after percutaneous coronary revascularization.

3 ban administered for at least 12 hours after percutaneous coronary revascularization.

4 mong patients undergoing successful elective percutaneous coronary revascularization.

5 intervention for secondary prevention after percutaneous coronary revascularization.

6 elevations (one to five times normal) after percutaneous coronary revascularization.

7 ssel diameter) who were scheduled to undergo percutaneous coronary revascularization.

8 mong a broad spectrum of patients undergoing percutaneous coronary revascularization.

9 tery syndromes and ischemic complications of percutaneous coronary revascularization.

10 protein IIb/IIIa receptors in the setting of percutaneous coronary revascularization.

11 assessing the operator-specific results for percutaneous coronary revascularization.

12 Restenosis remains the major limitation of percutaneous coronary revascularization.

13 th an acute coronary syndrome and undergoing percutaneous coronary revascularization.

14 stent significantly reduces restenosis after percutaneous coronary revascularization.

15 I and HF were less likely to receive primary percutaneous coronary revascularization (84% versus 79%

16 In the setting of percutaneous coronary revascularization, agents in the c

17 including 4603 patients undergoing elective percutaneous coronary revascularization and 1071 patient

18 Current treatment strategies for percutaneous coronary revascularization and acute corona

19 otein IIb/IIIa antagonist xemilofiban before percutaneous coronary revascularization and for up to si

20 Duke University Medical Center who underwent percutaneous coronary revascularization and received the

21 ients with acute ischemic syndromes or after percutaneous coronary revascularization and that persist

22 of adverse cardiovascular outcomes following percutaneous coronary revascularization, and higher oper

23 used for the majority of patients undergoing percutaneous coronary revascularization, and the body of

24 uidelines on continued medical therapy after percutaneous coronary revascularization are needed.

25 igned patients undergoing urgent or elective percutaneous coronary revascularization at 69 centers to

26 Patients who had undergone successful percutaneous coronary revascularization at the Mayo Clin

27 Successful percutaneous coronary revascularization did not substant

28 In high risk patients undergoing percutaneous coronary revascularization, features of thr

29 on long-term outcomes in patients undergoing percutaneous coronary revascularization for small vessel

30 Percutaneous coronary revascularization frequently relie

31 en administered intravenously at the time of percutaneous coronary revascularization, glycoprotein II

32 es clinical outcomes in the months following percutaneous coronary revascularization in a wide variet

33 dialysis patients undergoing surgical versus percutaneous coronary revascularization in the era of dr

34 During percutaneous coronary revascularization, intracoronary s

35 rocedural myocardial infarction complicating percutaneous coronary revascularization is associated wi

36 effect of smoking on the clinical outcome of percutaneous coronary revascularization is unknown.

37 Percutaneous coronary revascularization is widely used i

38 For percutaneous coronary revascularization, modeling to dis

39 ion with a 600-mg dose of clopidogrel before percutaneous coronary revascularization on early outcome

40 Despite advances in surgical and percutaneous coronary revascularization, ongoing ischemi

41 Coronary artery bypass graft (CABG) and percutaneous coronary revascularization (PCI) are strate

42 Percutaneous coronary revascularization (PCI) has been i

43 ts by extending clopidogrel >12 months after percutaneous coronary revascularization (PCI).

44 tries and prospective trials of surgical and percutaneous coronary revascularization procedures in di

45 l has reduced thrombotic complications after percutaneous coronary revascularization procedures.

46 c evaluation among 1,314 patients undergoing percutaneous coronary revascularization randomized to ei

47 and low-dose, weight-adjusted heparin during percutaneous coronary revascularization reduces ischemic

48 Future studies of percutaneous coronary revascularization should include r

49 hin a single-center registry of contemporary percutaneous coronary revascularization strategies with

50 cal outcomes of closure device use following percutaneous coronary revascularization using current st

51 A total of 2,306 patients undergoing percutaneous coronary revascularization was divided in g

52 ents who continued to smoke after successful percutaneous coronary revascularization were at greater

53 Patients undergoing percutaneous coronary revascularization were more likely

54 acute ischemic complications associated with percutaneous coronary revascularization, whereas coronar

55 al outcomes in high risk patients undergoing percutaneous coronary revascularization who received eit

56 e, or repeat revascularization compared with percutaneous coronary revascularization with drug-elutin

57 rolled in the SIRIUS trial and randomized to percutaneous coronary revascularization with either a SE

58 In this study, we compared percutaneous coronary revascularization with lipid-lower

59 her tirofiban or abciximab before undergoing percutaneous coronary revascularization with the intent

60 r placebo 30 to 90 minutes before undergoing percutaneous coronary revascularization, with maintenanc

61 hin 30 days by 56% among patients undergoing percutaneous coronary revascularization, without increas

62 schemic complications in patients undergoing percutaneous coronary revascularization, without increas